Search

Displaying results 2911 - 2920 of 7018 in total
  1. Drug

    EGS21

    go.drugbank.com/drugs/DB05056
    Experimental

    GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders.

  2. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. … Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  3. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. … M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.

  4. Drug

    Omega-3-acid ethyl esters

    go.drugbank.com/drugs/DB09539
    ApprovedInvestigational

    Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults wit...

  5. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Thrombin

    go.drugbank.com/drugs/DB11300
    ApprovedInvestigational

    Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. … A variety of human thrombin and recombinant thrombin (ie. thrombin alfa) products are available as alternatives to using bovine thrombin.

  7. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    Nitazoxanide belongs to the class of drugs known as _thiazolides_. … It is generally well tolerated.

    Products: N/a, XINPA 2 % POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL
  8. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. … It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis.

  9. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and … It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.

  10. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which … The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index